| Literature DB >> 22148514 |
Xiao-Yi Xiao1, Diana K Hunt, Jingye Zhou, Roger B Clark, Nick Dunwoody, Corey Fyfe, Trudy H Grossman, William J O'Brien, Louis Plamondon, Magnus Rönn, Cuixiang Sun, Wu-Yan Zhang, Joyce A Sutcliffe.
Abstract
This and the accompanying report (DOI: 10.1021/jm201467r ) describe the design, synthesis, and evaluation of a new generation of tetracycline antibacterial agents, 7-fluoro-9-substituted-6-demethyl-6-deoxytetracyclines ("fluorocyclines"), accessible through a recently developed total synthesis approach. These fluorocyclines possess potent antibacterial activities against multidrug resistant (MDR) Gram-positive and Gram-negative pathogens. One of the fluorocyclines, 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline (17j, also known as TP-434, 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Conference , Boston, MA , September 12-15, 2010 , poster F1 - 2157 ), is currently undergoing phase 2 clinical trials in patients with complicated intra-abdominal infections (cIAI).Entities:
Mesh:
Substances:
Year: 2012 PMID: 22148514 DOI: 10.1021/jm201465w
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446